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Background: Colorectal cancer is one of the most frequent and lethal cancers. The aim of 
this study was to analyze the costs relating to treatment of colorectal cancer between Xelox 
and Folfox-4 at a regional level according to the clinical experience at an Italian hospital in 
Lombardy.
Methods: A cost analysis was carried out regarding resource consumption by patients suffer-
ing from colorectal cancer based on data collected over a 12-month period between 2010 and 
2011. The analysis involved 40 patients who attended the Department of Medical Oncology and 
Hematology at Carlo Poma Hospital to undergo adjuvant therapy for colorectal cancer. A chart 
was created for each patient containing their medical history, their pharmacological therapy 
indicating the number and duration of chemotherapy cycles, dose in mg administered for each 
cycle, number of day hospital visits for each cycle, number of days spent in hospital to position 
the central vein catheter, type of infusion pump used, any subsequent supportive therapy, and 
any side effects and outpatient visits connected with side effects.
Results: The cost analysis shows the savings involved in using Xelox for a single cycle of 
treatment, ie, approximately €1414.00 per patient (53% compared with Folfox-4). For each 
single cycle of treatment, the savings generated by using capecitabine compared with 5-FU 
can be attributed mostly to the fact that oral administration of chemotherapy requires fewer 
resources and does not require use of a central vein catheter (approximately 70% of overall 
cost) which amply compensates for the higher cost of capecitabine compared with 5-FU-LV . 
Sensibility analysis confirms the results of the base-case scenario.
Conclusion: The results of our study indicate that infusion via a central vein catheter represents 
a significant cost, and that substitution with an oral therapy, even when associated with drugs 
administered intravenously, represents a consistent saving of hospital resources.
Keywords: colorectal cancer, capecitabine, oxaliplatin, 5-fluorouracil, Folfox-4, cost analysis, 
economic evaluation
Introduction
Colorectal cancer is one of the most common lethal cancers. In western countries, 
it is estimated that approximately 8% of all cancer deaths are caused by colorectal 
cancer, and standardized rates place Italy at a medium to low level for incidence (29.46 
cases/100,000 per year) and mortality (12.32 deaths/100,000 per year) compared with 
the European population as a whole.1,2 Approximately 40%–60% of patients survive 
for 3–5 years after diagnosis, depending on where the cancer is located.3 Treatment of 
colorectal cancer includes surgery, chemotherapy, and radiotherapy, or a combination 
of these.4 Chemotherapy is the standard of care in the treatment of colorectal cancer, 
but the efficacy of the different schedules of chemotherapy varies depending on the   
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combination of drugs administered. 5-Fluorouracil (5-FU) 
by infusion or pills has proven to be highly effective in the 
treatment of early or advanced colorectal cancer. In combina-
tion with folinic acid, it has increased the clinical response, 
and when associated with irinotecan or oxaliplatin, it has 
increased survival rates in patients.5,6 The guidelines suggest 
that 5-FU should preferably be administered by infusion.4,7 
Capecitabine administered orally as a single therapy has 
also proved to be highly effective in the first-line treatment 
of meta  static colorectal cancer, showing lower toxicity lev-
els and a notable reduction in side effects such as diarrhea, 
stomatitis, nausea, and neutropenia.8 Its efficacy, tolerability, 
and ease of administration make it suitable for use in col-
orectal cancer, particularly in older patients who are more 
exposed to the difficulties and inconvenience of frequent 
hospital visits to receive drugs intravenously which are often 
associated with a high risk of infection. These issues were an 
integral part of the 12-month evaluation using capecitabine + 
oxaliplatin (Xelox) and 5-FU + oxaliplatin (Folfox-4) in the 
treatment of colorectal cancer. Capecitabine is a new oral 
fluoropyrimidine carbamate selectively activated to 5-FU in 
tumor cells. It passes through the intestinal mucosal mem-
brane intact and is subsequently activated by a cascade of 
three enzymes, resulting in the preferential release of 5-FU 
at the tumor site. Randomized clinical studies have supported 
the indications of capecitabine as monotherapy and in combi-
nation with other chemotherapy drugs for patients suffering 
from metastatic colorectal cancer as an alternative to 5-FU 
administered by infusion.7,9 Analyses carried out within the 
Italian health care system10,11 have demonstrated that differ-
ences in the methods of administering the two drugs, (by 
infusion or orally), and their toxicity profiles affect patient 
quality of life. In a situation where best practice regarding 
resources should be used with the aim of safeguarding health, 
evaluation of health technology is of crucial importance. In 
addition, we must also take into account clinical consider-
ations and organizational and economic aspects, without 
forgetting the point of view of the patient, which extends 
the parameters used in analysis of the health environment to 
include the social context. From this perspective, pharmaco-
logical treatments must be examined within the context of the 
diagnostic, therapeutic, and care management program, given 
that the characteristics of the drugs modify the way in which 
treatment will be administered, which impacts organizational 
and economic aspects. The aim of this study was to compare 
costs relating to treatment between Xelox and Folfox-4 at a 
regional level, according to clinical experience at an Italian 
hospital in Lombardy.
Materials and methods
This was a retrospective study of 40 patients who under-
went surgery for stage III colorectal cancer followed by 
adjuvant chemotherapy using Xelox or Folfox-4. The Xelox 
group comprised 13 men and seven women of mean age 58 
(38–69) years. Fourteen patients had a performance status 
of 0 and six patients had a performance status of 1. The 
Folfox-4 group comprised 10 women and 10 men of mean age 
59 (42–69) years. Sixteen patients had a performance status 
of 0 and four patients had a performance status of 1. Given 
that this was a very recent study, data on recurrence rate 
and relapse-free survival are not yet available. An analysis 
was carried out regarding resource consumption for patients 
suffering from colorectal cancer based on data collected over 
a 12-month period between 2010 and 2011. The analysis 
involved 40 patients who attended the Department of Medical 
  Oncology and Hematology at Carlo Poma Hospital to undergo 
adjuvant therapy for colorectal cancer. A chart was created 
for each patient containing their medical history, pharmaco-
logical therapy, indicating the number and duration of the 
chemotherapy cycles, dose in mg administered for each cycle, 
number of day hospital visits for each cycle, number of days 
spent in hospital to position the central vein catheter, type of 
infusion pump used, any eventual supportive therapy, and any 
side effects and outpatient visits connected to side effects.
Consumption of resources
Using patient medical charts, the unit cost of each single 
drug and number of cycles administered, and their duration, 
the dose in mg for each cycle was calculated, yielding the 
cost per mg for each single drug used in the different cycles 
(Tables 1 and 2). The total cost of the different cycles admin-
istered was then estimated, to which the cost of administration 
was added, including the number of day hospital visits. The 
eventual use of a central vein catheter, complications arising 
from the central vein catheter, supportive therapy, diagnostic 
investigations, and control visits were counted and added to 
the total. Adverse effects relating to chemotherapy for both 
groups of treatment were taken on aggregate. Values attributed 
to the resources consumed were supplied by the Carlo Poma 
Hospital Administration Department. Information on standard 
therapeutic courses of treatment was collected, in particular 
on procedures relating to administration of chemotherapy, 
supportive therapy, and programmed control visits. Eventual 
day hospital visits were analyzed to exclude diagnosis-related 
group (DRG, inpatient tariff for hospital reimbursement) costs 
from the cost analysis to avoid costs being counted twice and 
to support further the results of the comparison study.
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Results
Table 3 shows the average cost per patient per cycle and 
overall duration of therapy for both treatment arms, high-
lighting the role of the resources involved. Calculations for 
this table were based on DRG tariffs, where available. The 
cost of all eventual equipment utilized and installation costs 
were added. Table 3 clearly shows the savings involved in 
using Xelox for a single cycle of treatment, which were 
approximately €1414.00 per patient (53% compared with 
Folfox-4). For each single cycle of treatment, the savings 
generated using capecitabine compared with 5-FU can 
mostly be attributed to the fact that oral administration of 
chemotherapy requires fewer resources and does not require 
use of a central vein catheter (approximately 70% of the 
overall cost) which amply compensates for the higher cost 
of capecitabine compared with 5-FU-LV . Figure 1 shows 
that the initial higher cost of the drug is offset by the sav-
ings resulting from less use of implants, catheters, and 
general maintenance of therapy. In order to strengthen our 
analysis, we hypothetically excluded DRG costs from the 
cost analysis. Once again, Xelox proved to be more advanta-
geous, with a cost reduction of 30% compared with Folfox-4 
(Figure 2).
Discussion
This analysis clearly indicates that clinical choices made in 
oncology based on the efficacy of therapy have economic 
repercussions and that the appropriateness of treatment must 
necessarily take this aspect into account considering, above 
all, the efficacy and safety of the treatments analyzed. The 
availability of oral therapy represents a valid alternative 
in the medical treatment of colorectal cancer, which has 
already been demonstrated in terms of efficacy and safety 
but poorly quantified in economic terms in the international 
or Italian literature. This retrospective study assessed the 
health costs generated by patients who underwent two che-
motherapy regimes, highlighting how administration costs 
can account for over 70% of costs involved in adjuvant 
chemotherapy.
From an economic point of view, the use of capecitabine 
means that medical staff spend less time administering 
therapy, which results in more efficient use of the day hos-
pital which, according to information obtained from DRG 
costs, has a different cost in every region (from €345 to €44). 
However, Lombardy uses a lower tariff than other regions. 
Administration by infusion using a central vein catheter 
involves substantial costs, whereas replacing it with oral 
therapy combined with drugs administered intravenously 
results in savings in health resources for the hospital which 
translates into a reduction in the time that the medical staff 
spend administering therapy and more efficient use of the 
day hospital. From the point of view of patient quality of life, 
Xelox requires fewer visits and takes less time to administer 
Table 2 Mean cycles and doses per patient in both arms
XELOX FOLFOX-4
Average cycles carried out 7 10.75
Cycle duration (days) 21 14
Average overall dose (mg) per cycle    
  Capecitabine 3187.50
  Oxaliplatin 214.75
  5-FU 3500.50
  LV 345.50
  Oxaliplatin   148.95
Table 3 Mean cost per patient by treatment and type of cost
XELOX FOLFOX-4
Drugs
  5-FU – €6.68
  LV – €30.57
  Capecitabine €247.10 –
  Oxaliplatin €731.93 €504.31
Total €979.03 €541.56
Administration and catheter positioning
  Positioning CVC – €648.89
  DRG and ambulatory visits €410.01 €1,229.03
Total €410.01 €1,877.93
Therapy maintenance costs
  Extra visits – €79.93
  Support therapy €13.06 €126.01
  CVC complications – €19.98
Total €13.06 €225.91
Total per cycle €1,402.10 €2,645.40
Difference €1,243.31
Total per complete treatment €9,814.68 €28,438.08
Difference €18,623.40
Table 1 Unit costs of the resources considered in the analysis
Treatment Unit cost (per mg)
5-FU €0.0020
LV €0.0930
Capecitabine €0.0056
Oxaliplatin €3.7100
Day hospital €424.00
Ambulatory visits (first/control visits) €22.51
Hospital admissions €2203.00
Day-surgery for CVC €219.00
Central venous catheter Portacath €21.38
Central venous catheter Groshon €359.50
Disposable baxter infusion elastomeric pump €11.61
ECG €16.92
Kit for CVC positioning €10.80
Abbreviations: LV, Leucovorin; CVC, Central Vein Catheter.
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than Folfox-4. This improves patient quality of life because 
it reduces the number of hospital visits. Oxaliplatin is admin-
istered as a 2-hour infusion on both schedules, but Folfox-4 
also requires insertion of a central vein catheter (for a 2-day 
infusion of 5-FU) which can be upsetting for patients because 
it has a physical and a psychological impact and can lead to 
complications such as infections, bleeding, pneumothorax, 
and venous thromboembolism.
Our study is somewhat limited given that it was carried out 
in a single hospital with a relatively small number of patients. 
Therefore, these results cannot be considered representative 
of current clinical practice, even though the therapies and 
methods used reflect a certain standard in many oncological 
departments. It should also be noted that, in our experience, 
a central vein catheter has not resulted in infections or other 
complications related to central vein catheterization, which 
have been amply described in the literature. In centers with 
less experience, these complications could have a greater 
impact and could therefore lead to additional costs. However, 
taking the necessary precautions, use of capecitabine instead 
of 5-FU in the Xelox schedule has led to a reduction in hos-
pital visits and adverse events, and a general improvement in 
patient quality of life, together with a reduction in the global 
cost of treatment compared with Folfox-4.
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Figure 1 Mean cost per patient by treatment and type of cost.
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Figure 2 Sensibility analysis excluding diagnosis-related group costs.
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However, our results are in line with those of other 
  European studies carried out in metastatic patients. An Italian 
study compared the costs for patients involved in a clinical 
study comparing capecitabine with 5-FU in single therapy, 
estimating a saving of €823 per patient over 6 months of 
treatment, with a cost driver represented by the cost of chemo-
therapy in the capecitabine arm and by infusion in the 5-FU 
arm.10,12 A recent retrospective study carried out in France 
estimated a saving of €2000–€7200, depending on the 5-FU 
chemotherapy regime.13 A recent report by the English Health 
Technology Assessment estimated a saving per patient for 
capecitabine compared with a modified de Gramont regime 
carried out in hospital of €5100.14 In conclusion, the results 
of our study indicate that drug infusion through a central 
vein catheter represents significant costs and that substitu-
tion with an oral therapy, even when associated with drugs 
administered intravenously, represents a consistent saving of 
resources for the hospital. It is our opinion that further studies 
should be carried out, with the aim of establishing this type 
of analysis as a guide for doctors and hospital administrators 
in their choices of health strategies.
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